Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma

(2013) Daniel E. Schwed Lustgarten et al.   Journal of Thoracic Oncology

Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin

(2013) Seung Hyeun Lee et al.   LUNG CANCER

A genomic view of mosaicism and human disease

(2013) Leslie G. Biesecker et al.   NATURE REVIEWS GENETICS

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

(2013) Silvy Laporte et al.   BMJ Open

Pemetrexed for Previously Treated Patients with Non-Small Cell Lung Cancer and Differences in Efficacy according to Thymidylate Synthase Expression

(2012) Satoshi Igawa et al.   CHEMOTHERAPY

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer

(2012) Murry W. Wynes et al.   Journal of Thoracic Oncology

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

(2012) Daniel C. Christoph et al.   Journal of Thoracic Oncology

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

(2012) Chandra P Belani et al.   LANCET ONCOLOGY

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

(2012) Marcello Tiseo et al.   LUNG CANCER

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population

(2011) F. Tanaka et al.   ANNALS OF ONCOLOGY

Biomarker analysis in a phase III study of pemetrexed–carboplatin versus etoposide–carboplatin in chemonaive patients with extensive-stage small-cell lung cancer

(2011) E. F. Smit et al.   ANNALS OF ONCOLOGY

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

(2011) K Takezawa et al.   BRITISH JOURNAL OF CANCER

Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer

(2011) Shirish M. Gadgeel et al.   Journal of Thoracic Oncology

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

(2011) Jong-Mu Sun et al.   Journal of Thoracic Oncology

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial

(2011) Chandra Prakash Belani et al.   Journal of Thoracic Oncology

Expression Profiling-Based Subtyping Identifies Novel Non-small Cell Lung Cancer Subgroups and Implicates Putative Resistance to Pemetrexed Therapy

(2011) Jun Hou et al.   Journal of Thoracic Oncology

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed

(2011) Chung-Yu Chen et al.   LUNG CANCER

Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations

(2011) Richard A. Hubner et al.   PLoS One

Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy

(2010) Luisella Righi et al.   JOURNAL OF CLINICAL ONCOLOGY

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer

(2010) Myung Hee Chang et al.   LUNG CANCER

Biological Prognostic and Predictive Factors in Lung Cancer

(2010) Antonio Rossi et al.   ONCOLOGY

Updated Clinical Information on Multitargeted Antifolates in Lung Cancer

(2009) Giorgio V. Scagliotti et al.   Clinical Lung Cancer

Correlation Between Thymidylate Synthase Protein Expression and Gene Polymorphism with Clinicopathological Parameters in Colorectal Carcinoma

(2009) Luciana R. Moreira et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer

(2009) Egbert F. Smit et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer

(2008) Zhong Zheng et al.   CANCER

Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer

(2008) Gerold Bepler et al.   Journal of Thoracic Oncology